FIELD: medicine, rheumatology.
SUBSTANCE: invention can be used for treatment of patients with ankylosing spondylarthritis. Method involves using prospidin in the dose 300 mg per a week by intravenous route administration as the basic therapy on stationary stage and then in the dose 100-200 mg by intramuscular administration on ambulatory stage. Method provides the early and prolonged clinical effect in treatment.
EFFECT: enhanced effectiveness of treatment.
6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING RHEUMATOID ARTHRITIS | 2001 |
|
RU2199320C1 |
| METHOD FOR TREATMENT OF PSORIATIC ARTHRITIS | 2003 |
|
RU2228755C1 |
| METHOD FOR PREVENTING OSSEOUS-CARTILAGINOUS DESTRUCTION IN CASE OF RHEUMATOID ARTHRITIS | 2003 |
|
RU2268719C2 |
| METHOD FOR TREATING CHRONIC GONARTHRITIS IN PATIENTS WITH OSTEOARTHROSIS | 2005 |
|
RU2293560C2 |
| METHOD OF TREATING PSORIATIC ARTHROPATHY PATIENTS | 0 |
|
SU1602522A1 |
| METHOD FOR TREATING THE CASES OF RHEUMATOID ARTHRITIS | 2003 |
|
RU2268074C2 |
| METHOD FOR TREATMENT OF JUVENILE RHEUMATIC ARTHRITIS | 1991 |
|
RU2018320C1 |
| METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLARTHRITIS BY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | 2016 |
|
RU2728710C2 |
| METHOD OF STEROID-DEPENDANT RHEUMATOID ARTHRITIS TREATMENT | 2006 |
|
RU2326675C2 |
| THERAPY OF PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS WITH APPLYING COMBINATION OF TUMOUR NECROSIS ALPHA FACTOR ANTIBODIES | 2007 |
|
RU2360717C1 |
